EN DE
Watch Hebei Changshan Biochem Pharma for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Hebei Changshan Biochem Pharma (300255) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Hebei Changshan Biochem Pharma stock ¥11.69, price ¥17.82, that is 34.4% below the price, quality 35 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CN · ISIN CNE1000016C2

HC Hebei Changshan Biochem Pharma logo Thin data Nov 16, 2026

Hebei Changshan Biochem Pharma

300255 · SHE

Expensive (fair value 34% below the price), weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Low debt 
Last quarter vs. a year ago: revenue +37%, profit +56%. 
Fair value ¥11.69 · Overvalued 
Quality 35/100 
Falling price (downtrend) 
Weak Growth (revenue 5y −18.0 %/yr in CNY) 
Loss-making · -37.7% net margin (TTM) 
Negative free cash flow 
Trails peers (4/11) 
Narrow moat 14/100
Thin data 
Estimate
Watch Hebei Changshan Biochem Pharma for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥69.80 ¥4.44 Fair Value ¥11.69 Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range ¥4.44 – ¥69.80 · fair‑value band ¥8.77 – ¥14.61 · the ¥17.82 price screens above the ¥11.69 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow Hebei Changshan Biochem Pharma in your weekly email

Every Wednesday you see whether Hebei Changshan Biochem Pharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Hebei Changshan Biochemical Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, marketing, and sale of drugs for cardiovascular, cerebrovascular, diabetes, and cancer in China and internationally.

Show moreShow less

It offers heparin sodium, calcium, and lithium, as well as heparinoid, LMW heparins, and sodium hyaluronate; dalteparin sodium, enoxaparin sodium, nadroparin calcium, and heparin sodium injections, as well as sildenafil citrate tablet; and albenatide.

The company is also involved in technology development; consulting; transfer services; investment and management of medical service projects; wholesale and retail of pharmaceuticals; and diagnosis services.

It exports its products to the United States, Germany, France, Italy, Spain, South Korea, Japan, Russia, India, the Philippines, and other countries. The company was founded in 1992 and is based in Shijiazhuang, China.

Stock analysis

Hebei Changshan Biochem Pharma (300255) currently trades at ¥17.82, while our estimate is ¥11.69, 34% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: ¥8.77 (bear) to ¥14.61 (bull), the price of ¥17.82 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Hebei Changshan Biochem Pharma reported revenue of 875M CNY in FY2025 versus 3.0B CNY in FY2021, a compound −26.3%/yr. Reported net income was −358M CNY in FY2025.

Key figures

Market cap 16.4B CNY (≈ $2.5B) Mid · P/S ratio 19.5 · EPS (TTM) ¥−0.3800 · Dividend yield 0.7% · Net margin −37.7% · Return on equity −27.4% · Return on assets (EBIT) −5.8% (5-year average) · Operating margin 7.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 14 out of 100 (medium confidence).

What moves the price

The share trades about 74% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −34%, 300255 screens richer than that median.

Fair Value

Bear ¥8.77 Fair Value ¥11.69 Bull ¥14.61
Price ¥17.82 · Downside -34.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 35/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 2
How much profit the company makes from its sales and capital
Quality Growth 32
Are margins and returns getting better?
Cashflow 11
Do the profits arrive as real cash?
Financial strength 41
Debt, balance sheet and risk of trouble
Investment 78
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 2
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 84
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−15.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−27.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−18.0%
Start year 2020 (pandemic). Over 10 years: −0.5% a year
Revenue growth 17 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
13.1% (2020) → −10.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

300255 screens overvalued: fair value 34% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Hebei Changshan Biochem Pharma with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 848 stocks

Beats the industry median on 3/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 35 · Below median
Fair Value upside −34.4% · Below median
Profitability
Return on assets −8.2% · Above median
Net margin (12 months) −37.7% · Below median
Operating margin (12 months) 7.2% · Above median
Growth and dividend
Revenue growth (quarter YoY) 37.4% · Above median
Dividend yield (12 months) 0.7% · Below median
Balance sheet
Debt / equity 0.49× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 13.60× · Priciest 25%
P/S (12 months) 17.61× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 1
FUTURE (revenue growth)100 · sector 36
PAST (return on equity)0 · sector 0
HEALTH (low debt)76 · sector 96
DIVIDEND (yield)13 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs 300255
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs 300255
Samsung Biologics Co 207940 1,423,000 KRW 1,552,100 KRW +9% vs 300255
argenx SE ARGX $950.95 $908.40 −4% vs 300255
CSL Limited CSL A$199.55 A$186.49 −7% vs 300255
Moderna, Inc MRNA $215.27 $135.64 −37% vs 300255
BeOne Medicines AG 6160 HK$249.40 HK$152.92 −39% vs 300255
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs 300255
Celltrion, Inc 068270 214,500 KRW 74,945 KRW −65% vs 300255
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs 300255

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Hebei Changshan Biochem Pharma: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Hebei Changshan Biochem Pharma Fair Value". https://www.fairvalue-calculator.com/stock/300255

Frequently asked questions

Is Hebei Changshan Biochem Pharma (300255) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is ¥11.69 versus a price of ¥17.82, about 34% lower (overvalued).
What is the fair value of 300255?
Our estimate for Hebei Changshan Biochem Pharma is ¥11.69 (as of Nov 16, 2026), built from audited fundamentals. The current price: ¥17.82.
What is the quality score of 300255?
Hebei Changshan Biochem Pharma has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hebei Changshan Biochem Pharma (300255)?
Our calculated price target is the estimate of ¥11.69 (as of Nov 16, 2026). Cautious scenario ¥8.77, optimistic scenario ¥14.61. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Hebei Changshan Biochem Pharma stock forecast for 2026?
Our estimate puts fair value at ¥11.69, about 34% lower versus a price of ¥17.82 (overvalued). Cautious scenario ¥8.77, optimistic scenario ¥14.61. The calculation is refreshed regularly with new filings.
What is the revenue of Hebei Changshan Biochem Pharma (300255)?
Hebei Changshan Biochem Pharma reported trailing-twelve-month revenue of about 930M CNY (latest available figure, as of Nov 16, 2026).
Does Hebei Changshan Biochem Pharma pay a dividend?
Hebei Changshan Biochem Pharma currently shows a dividend yield of 0.65% relative to its recent price (as of Nov 16, 2026).
How much is the dividend of Hebei Changshan Biochem Pharma (300255)?
Hebei Changshan Biochem Pharma has a dividend yield of 0.7%.
What is the intrinsic value of Hebei Changshan Biochem Pharma (300255)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hebei Changshan Biochem Pharma it is ¥11.69 per share (as of Nov 16, 2026), against a price of ¥17.82.
Is Hebei Changshan Biochem Pharma stock overvalued or undervalued in 2026?
As of Nov 16, 2026, 300255 trades above its calculated fair value: price ¥17.82, fair value ¥11.69, a gap of about −34% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 300255?
No. The price is what the market pays today (¥17.82); the fair value is what the company's own numbers justify (¥11.69). For Hebei Changshan Biochem Pharma the two are ¥6.13 per share apart. That gap is exactly why we show both numbers side by side.
How much is Hebei Changshan Biochem Pharma worth?
The market values Hebei Changshan Biochem Pharma at about 16.4B CNY (market capitalisation, as of Nov 16, 2026). Per share that is ¥17.82; our models calculate a fair value of ¥11.69 per share.
What do the bullish and bearish scenarios say about 300255?
Our models span a range for Hebei Changshan Biochem Pharma: cautious scenario ¥8.77, base ¥11.69, optimistic ¥14.61 per share (as of Nov 16, 2026, price ¥17.82). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Hebei Changshan Biochem Pharma (300255)?
Balance-sheet figures for Hebei Changshan Biochem Pharma (as of Nov 16, 2026): return on equity −27.4%, debt of 0.49 per unit of equity. They feed the Quality Score of 35/100, which measures business quality independently of the share price.
How far is 300255 from its 52-week high?
Hebei Changshan Biochem Pharma trades at ¥17.82, about 74% below its 52-week high of ¥68.32 and at the low of ¥17.82 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of ¥11.69 is for.
Which stocks are comparable to Hebei Changshan Biochem Pharma?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hebei Changshan Biochem Pharma stock attractive at the current price?
The data as of Nov 16, 2026: price ¥17.82, calculated fair value ¥11.69 (−34%), Quality Score 35/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Hebei Changshan Biochem Pharma itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hebei Changshan Biochem Pharma (300255)?
The closing price on Nov 16, 2026 was ¥17.82. Our estimate is ¥11.69, about 34% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hebei Changshan Biochem Pharma right now?
The price sits above even our optimistic bull case (¥14.61). The favourable scenario is already priced in. Weak quality (35/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Hebei Changshan Biochem Pharma

How large is the market capitalisation of Hebei Changshan Biochem Pharma (300255)?
The market capitalisation of Hebei Changshan Biochem Pharma is 16.4B CNY (≈ $2.5B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Hebei Changshan Biochem Pharma (300255)?
The price-to-sales ratio of Hebei Changshan Biochem Pharma is 19.5 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Hebei Changshan Biochem Pharma (300255)?
Earnings per share at Hebei Changshan Biochem Pharma are ¥−0.3800. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Hebei Changshan Biochem Pharma (300255)?
The dividend yield of Hebei Changshan Biochem Pharma is 0.7%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Hebei Changshan Biochem Pharma (300255)?
The net margin of Hebei Changshan Biochem Pharma is −37.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Hebei Changshan Biochem Pharma (300255)?
The return on equity (ROE) of Hebei Changshan Biochem Pharma is −27.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hebei Changshan Biochem Pharma (300255)?
On an EBIT basis the return on assets of Hebei Changshan Biochem Pharma is −5.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hebei Changshan Biochem Pharma (300255)?
The operating margin of Hebei Changshan Biochem Pharma is 7.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Hebei Changshan Biochem Pharma (300255)?
Revenue at Hebei Changshan Biochem Pharma is growing 37.4% versus a year earlier (3y avg −27.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Hebei Changshan Biochem Pharma (300255)?
Earnings per share at Hebei Changshan Biochem Pharma are growing 56.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Hebei Changshan Biochem Pharma (300255) generate?
The free cash flow of Hebei Changshan Biochem Pharma is −67.7M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Hebei Changshan Biochem Pharma (300255) carry?
The net debt of Hebei Changshan Biochem Pharma is 1.8B CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Hebei Changshan Biochem Pharma in the live analysis

One click puts Hebei Changshan Biochem Pharma on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.